文献速递头颈外科

局部晚期头颈癌根治性局部区域治疗后监测评估计划优化:基于无事件生存参数模型的回顾性队列研究

Evaluation of Optimal Assessment Schedules for Surveillance After Definitive Locoregional Treatment of Locally Advanced Head and Neck Cancer: A Retrospective Cohort Study With Parametric Modeling of Event-Free Survival.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2022-01-01

该回顾性队列研究纳入2家三级转诊医院673例局部晚期头颈癌根治性治疗患者,按原发亚部位和HPV状态分层,用分段指数模型拟合无事件生存曲线并以5%事件率标准确定最佳随访时间点和间隔。研究建议随访计划应个体化并基于证据,考虑原发亚部位和HPV状态。

要点

  • 按原发亚部位和HPV状态分层的参数模型可确定局部晚期头颈癌最佳随访间隔。
  • 下咽癌建议随访间隔最短,HPV阳性口咽癌最长。
  • 研究建议随访计划应个体化并基于证据以考虑原发亚部位和HPV状态。

核心结论

  • 该回顾性队列研究使用参数模型提示头颈癌评估计划应个体化并基于证据,考虑原发亚部位和HPV状态。
  • 鉴于医疗资源有限及头颈癌检出率和费用上升,这些发现提供的指导可能有益于患者和卫生系统,并有助于制定未来的共识指南。

研究设计与样本

  • 回顾性研究,纳入2家三级转诊医院共673例接受根治性局部区域治疗的局部晚期头颈癌患者。
  • 患者包括鼻咽癌227例、HPV阳性口咽癌237例、HPV阴性口咽癌47例、下咽癌65例和喉癌97例。
  • 患者于2008年至2019年接受主要治疗,中位(范围)随访时间为57.8(6.4-158.1)个月。
  • 数据分析于2021年4月至10月进行,主要结局为肿瘤复发和第二原发恶性肿瘤。
  • 无事件生存期定义为从治疗结束到发生任何事件的时间,采用分段指数模型估计无事件生存曲线并分为3个规律随访阶段,以5%事件率标准确定最佳随访时间点和间隔。

主要发现

  • 673例患者诊断头颈癌时中位(范围)年龄为58(15-83)岁,555例(82.5%)为男性。
  • 鼻咽癌、HPV阳性口咽癌、HPV阴性口咽癌、下咽癌和喉癌的事件率分别为18.9%(43/227)、14.8%(35/237)、36.2%(17/47)、44.6%(29/65)和30.9%(30/97)。
  • 下咽癌、喉癌和鼻咽癌的最佳随访间隔分别为每2.1、3.2和6.1个月(直至治疗后16.5个月),每3.7、5.6和10.8个月(16.5至25.0个月),每9.1、13.8和26.5个月(25.0至99.0个月),此后开放随访。
  • HPV阴性口咽癌建议在治疗后16.5个月内、16.5至25.0个月、25至99个月分别每2.7、4.8和11.8个月评估一次。
  • HPV阳性口咽癌最佳间隔分别为在治疗后16.5个月内、16.5至25.0个月、25至99个月每7.7、13.7和33.7个月一次;鼻咽癌、HPV阳性口咽癌、HPV阴性口咽癌、下咽癌和喉癌建议随访次数分别为5、4、12、15和10次。

关键数值与推荐

  • 以5%事件率标准确定最佳随访时间点和间隔。
  • 下咽癌最佳随访间隔为每2.1、3.7和9.1个月(分别对应治疗后16.5个月内、16.5至25.0个月、25.0至99.0个月),此后开放随访。
  • 喉癌最佳随访间隔为每3.2、5.6和10.8个月(分别对应治疗后16.5个月内、16.5至25.0个月、25.0至99.0个月),此后开放随访。
  • 鼻咽癌最佳随访间隔为每6.1、10.8和26.5个月(分别对应治疗后16.5个月内、16.5至25.0个月、25.0至99.0个月),此后开放随访。
  • HPV阴性口咽癌建议在治疗后16.5个月内、16.5至25.0个月、25至99个月分别每2.7、4.8和11.8个月评估一次;HPV阳性口咽癌最佳间隔分别为每7.7、13.7和33.7个月一次。

临床怎么用

  • 作者认为头颈癌评估计划应个体化并基于证据,考虑原发亚部位和HPV状态。
  • 作者认为这些发现提供的指导可能有益于患者和卫生系统,并有助于制定未来的共识指南。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: In clinical practice, assessment schedules are often arbitrarily determined after definitive treatment of head and neck cancer (HNC), producing heterogeneous and inconsistent surveillance plans. OBJECTIVE: To establish an optimal assessment schedule for patients with definitively treated locally advanced HNC, stratified by the primary subsite and HPV status, using a parametric model of standardized event-free survival curves. DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective study including 2 tertiary referral hospitals and a total of 673 patients with definitive locoregional treatment of locally advanced HNC (227 patients with nasopharyngeal cancer [NPC]; 237 patients with human papillomavirus-positive oropharyngeal cancer [HPV+ OPC]; 47 patients with HPV-negative [HPV-] OPC; 65 patients with hypopharyngeal cancer [HPC]; and 97 patients with laryngeal cancer [LC]). Patients had received primary treatment in 2008 through 2019. The median (range) follow-up duration was 57.8 (6.4-158.1) months. Data analyses were performed from April to October 2021. MAIN OUTCOMES AND MEASURES: Tumor recurrence and secondary malignant neoplasms. Event-free survival was defined as the period from the end of treatment to occurrence of any event. Event-free survival curves were estimated using a piecewise exponential model and divided into 3 phases of regular follow-up. A 5% event rate criterion determined optimal follow-up time point and interval. RESULTS: The median (range) age of the 673 patients at HNC diagnosis was 58 (15-83) years; 555 (82.5%) were men; race and ethnicity were not considered. The event rates of NPC, HPV+ OPC, HPV- OPC, HPC, and LC were 18.9% (43 of 227), 14.8% (35 of 237), 36.2% (17 of 47), 44.6% (29 of 65), and 30.9% (30 of 97), respectively. Parametric modeling demonstrated optimal follow-up intervals for HPC, LC, and NPC, respectively, every 2.1, 3.2, and 6.1 months; 3.7, 5.6, and 10.8 months; and 9.1, 13.8, and 26.5 months until 16.5, 16.5 to 25.0, and 25.0 to 99.0 months posttreatment (open follow-up thereafter). For HPV- OPC, assessment was recommended every 2.7, 4.8, and 11.8 months until 16.5, 16.5 to 25.0, and 25 to 99 months posttreatment, respectively. In contrast, HPV+ OPC optimal intervals were every 7.7, 13.7, and 33.7 months until 16.5, 16.5 to 25.0, and 25 to 99 months posttreatment, respectively. Five, 4, 12, 15, and 10 follow-up visits were recommended for NPC, HPV+ OPC, HPV- OPC, HPC, and LC, respectively. CONCLUSIONS AND RELEVANCE: This retrospective cohort study using parametric modeling suggests that the HNC assessment schedules should be patient tailored and evidence based to consider primary subsites and HPV status. Given limited health care resources and rising detection rates and costs of HNC, the guidelines offered by these findings could benefit patients and health systems and aid in developing future consensus guidelines.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Lee HI, Lee J, Lee JH, et al. Evaluation of Optimal Assessment Schedules for Surveillance After Definitive Locoregional Treatment of Locally Advanced Head and Neck Cancer: A Retrospective Cohort Study With Parametric Modeling of Event-Free Survival. JAMA Otolaryngol Head Neck Surg. 2022. PMID: 36173618. doi:10.1001/jamaoto.2022.2561

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。